ASP8062

DRUG6 trials

Sponsors

Astellas Pharma Global Development, Inc., Astellas Pharma Inc, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Conditions

Alcohol DrinkingAlcohol Use DisorderAlcohol Use Disorder (AUD)FibromyalgiaHealthy VolunteersOpioid Use Disorder

Phase 1

Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects

CompletedNCT03183739

Astellas Pharma IncHealthy Volunteers

Start: 2017-06-20End: 2017-10-06Updated: 2024-10-21

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

CompletedNCT04003402

Astellas Pharma Global Development, Inc.Healthy Volunteers

Start: 2019-07-16End: 2019-10-16Updated: 2024-11-05

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

CompletedNCT04447287

Astellas Pharma Global Development, Inc.Opioid Use Disorder

Start: 2020-06-29End: 2020-11-25Updated: 2024-11-21

Phase 2

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

CompletedNCT03092726

Astellas Pharma Global Development, Inc.Fibromyalgia

Start: 2017-05-08End: 2018-03-06Updated: 2025-11-03

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

WithdrawnNCT05062577

Astellas Pharma Global Development, Inc.Opioid Use Disorder

Start: 2021-11-08End: 2023-02-28Updated: 2024-11-06

Human Laboratory Study of ASP8062 for Alcohol Use Disorder

CompletedNCT05096117

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Alcohol Drinking, Alcohol Use Disorder, Alcohol Use Disorder (AUD)

Start: 2021-12-13End: 2023-03-22Updated: 2024-12-03

Related Papers

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder

Journal of Psychopharmacology2023-02-013 citations